{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:37:02Z","timestamp":1791419822027,"version":"4.3.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Canada Graduate Student Scholarship"},{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2016-05055"],"award-info":[{"award-number":["RGPIN-2016-05055"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["375104\/2017"],"award-info":[{"award-number":["375104\/2017"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010564","name":"Academic Medical Organization of Southwestern Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early response to antipsychotic medications is one of the most important determinants of later symptomatic and functional outcomes in psychosis. Glutathione and glutamate have emerged as promising therapeutic targets for patients demonstrating inadequate response to dopamine-blocking antipsychotics. Nevertheless, the role of these neurochemicals in the mechanism of early antipsychotic response remains poorly understood. Using a longitudinal design and ultrahigh field 7-T magnetic resonance spectroscopy (MRS) protocol in 53 subjects, we report the association between dorsal anterior cingulate cortex glutamate and glutathione, with time to treatment response in drug naive (34.6% of the sample) or minimally medicated first episode patients with schizophreniform disorder, schizophrenia, and schizoaffective disorder. Time to response was defined as the number of weeks required to reach a 50% reduction in the PANSS-8 scores. Higher glutathione was associated with shorter time to response (\n                    <jats:italic>F<\/jats:italic>\n                    \u2009=\u20094.86,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.017), while higher glutamate was associated with more severe functional impairment (\n                    <jats:italic>F<\/jats:italic>\n                    \u2009=\u20095.33,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.008). There were no significant differences between patients and controls on measures of glutamate or glutathione. For the first time, we have demonstrated an association between higher glutathione and favorable prognosis in FEP. We propose that interventions that increase brain glutathione levels may improve outcomes of early intervention in psychosis.\n                  <\/jats:p>","DOI":"10.1038\/s41380-020-0704-x","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T22:03:45Z","timestamp":1585001025000},"page":"1640-1650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate"],"prefix":"10.1038","volume":"25","author":[{"given":"Kara","family":"Dempster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"MacKinley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-4469","authenticated-orcid":false,"given":"Jean","family":"Th\u00e9berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1640-7182","authenticated-orcid":false,"given":"Lena","family":"Palaniyappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"704_CR1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1192\/bjp.bp.109.069328","volume":"196","author":"R Schennach-Wolff","year":"2010","unstructured":"Schennach-Wolff R, Seemuller FH, Mayr A, Maier W, Klingberg S, Heuser I, et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry. 2010;196:460\u20136.","journal-title":"Br J Psychiatry"},{"key":"704_CR2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.psychres.2010.11.017","volume":"187","author":"VL Stauffer","year":"2011","unstructured":"Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011;187:42\u20138.","journal-title":"Psychiatry Res"},{"key":"704_CR3","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4088\/JCP.v67n1106","volume":"67","author":"R Emsley","year":"2006","unstructured":"Emsley R, Osthulzen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry. 2006;67:1707\u201312.","journal-title":"J Clin Psychiatry"},{"key":"704_CR4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","volume":"102","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230\u201340.","journal-title":"Schizophr Res"},{"key":"704_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1004640408501","volume":"71","author":"JP Lindenmayer","year":"2000","unstructured":"Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000;71:373\u201384.","journal-title":"Psychiatr Q"},{"key":"704_CR6","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","volume":"46","author":"J Lally","year":"2016","unstructured":"Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance in first-episode schizophrenia-spectrum psychoses. Psychol Med. 2016;46:3231\u201340.","journal-title":"Psychol Med"},{"key":"704_CR7","doi-asserted-by":"crossref","unstructured":"Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981\u20139.","DOI":"10.1017\/S0033291717000435"},{"key":"704_CR8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","volume":"152","author":"EMP Poels","year":"2014","unstructured":"Poels EMP, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152:325\u201332.","journal-title":"Schizophr Res"},{"key":"704_CR9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry. 2016;73:665\u201374.","journal-title":"JAMA Psychiatry"},{"key":"704_CR10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","volume":"5","author":"S Jauhar","year":"2018","unstructured":"Jauhar S, McCutcheon R, Borgan F, Veronese M, Nour M, Pepper F, et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry. 2018;5:816\u201323.","journal-title":"Lancet Psychiatry"},{"key":"704_CR11","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","volume":"97","author":"A Abi-Dargham","year":"2000","unstructured":"Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles L, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97:8104\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"704_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29:97\u2013115. https:\/\/doi.org\/10.1177\/0269881114563634.","journal-title":"J Psychopharmacol"},{"key":"704_CR13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","volume":"42","author":"E Mouchlianitis","year":"2016","unstructured":"Mouchlianitis E, Bloomfield MAP, Law V, Beck K, Selvaraj S, Naresh Rasquinha, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42:744\u201352.","journal-title":"Schizophr Bull"},{"key":"704_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2013.04.051","volume":"547","author":"A Szulc","year":"2013","unstructured":"Szulc A, Konarzewska B, Galinska-Skok B, Lazarczyk J, Waszkiewicz N, Tarasow E, et al. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci Lett. 2013;547:37\u201341.","journal-title":"Neurosci Lett"},{"key":"704_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biopsych.2013.06.011","volume":"75","author":"A Demjaha","year":"2014","unstructured":"Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:11\u20133.","journal-title":"Biol Psychiatry"},{"key":"704_CR16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2012.113","volume":"37","author":"A Egerton","year":"2012","unstructured":"Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe GJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37:2515\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"704_CR17","doi-asserted-by":"crossref","unstructured":"Egerton A, Broberg BV, Van Haren N, Merrit K, Barker GJ, Lythcoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicenter 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145\u201355.","DOI":"10.1038\/s41380-018-0082-9"},{"key":"704_CR18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pnpbp.2018.03.016","volume":"86","author":"Y Iwata","year":"2018","unstructured":"Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, et al. Neurometabolite levels in antipsychotic-na\u00efve\/free patients with schizophrenia: a systematic review and meta-analysis of 1H-MRS studies. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;86:340\u201352.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"704_CR19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1192\/bjp.bp.110.079608","volume":"198","author":"N Aoyoma","year":"2011","unstructured":"Aoyoma N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011;198:448\u201356.","journal-title":"Br J Psychiatry"},{"key":"704_CR20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.pscychresns.2015.06.003","volume":"233","author":"K Dempster","year":"2015","unstructured":"Dempster K, Norman R, Theberge J, Densmore M, Schaefer B, Williamson P. Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia. Psychiatry Res Neuroimaging. 2015;233:180\u20135.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"704_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0920-9964(95)00049-6","volume":"19","author":"SP Mahadik","year":"1996","unstructured":"Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res. 1996;19:1\u201317.","journal-title":"Schizophr Res"},{"key":"704_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","volume":"19","author":"KQ Do","year":"2009","unstructured":"Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neuobiol. 2009;19:220\u201330.","journal-title":"Curr Opin Neuobiol"},{"key":"704_CR23","doi-asserted-by":"crossref","unstructured":"Wang AM, Pradhan S, Coughlin JM, Trivedi A, DubBois SL, Crawford JL, et al. Assessing brain metabolism with 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis. JAMA Psychiatry. 2019;76:314\u201323.","DOI":"10.1001\/jamapsychiatry.2018.3637"},{"key":"704_CR24","doi-asserted-by":"crossref","unstructured":"Das TK, Javadzadeh A, Dey A, Sabesan P, Theberge J, Radua J, et al. Antioxidant defense in schizophrenia and bipolar disorder: a meta-analysis of MRS studies of anterior cingulate glutathione. Prog Neuropsychopharmacol Biol Psychiatry. 2019;91:94\u2013102.","DOI":"10.1016\/j.pnpbp.2018.08.006"},{"key":"704_CR25","doi-asserted-by":"publisher","unstructured":"Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, et al. Glutathione and Glutamate in schizophrenia: a 7T MRS Study. Mol Psychiatry. 2018. https:\/\/doi.org\/10.1038\/s41380-018-0104-7.","DOI":"10.1038\/s41380-018-0104-7"},{"key":"704_CR26","first-page":"5133","volume":"44","author":"P Klauser","year":"2018","unstructured":"Klauser P, Xin L, Fournier M, Griffa A, Cleusix M, Jenni R, et al. N-acetyl-cysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis. Schizophr Bull. 2018;44:5133\u20134.","journal-title":"Schizophr Bull"},{"key":"704_CR27","doi-asserted-by":"crossref","unstructured":"Sedlak TW, Paul BD, Parker GM, Hester LD, Snowman AM, Taniguchi Y, et al. The glutathione cycle shapes synaptic glutamate activity. PNAS 2019;116:2701\u20136","DOI":"10.1073\/pnas.1817885116"},{"key":"704_CR28","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1523\/JNEUROSCI.14-05-02924.1994","volume":"14","author":"A Volterra","year":"1994","unstructured":"Volterra A, Trotti D, Tromba C, Floridi S, Racagni G. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J Neurosci. 1994;14:2924\u201332.","journal-title":"J Neurosci"},{"key":"704_CR29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1471-4159.2008.05216.x","volume":"105","author":"J Frade","year":"2008","unstructured":"Frade J, Pope S, Schmidt M, Dringen R, Barbosa R, Pacock J, et al. Glutamate induces release of glutathione from cultured rat astrocytes- a possible neuroprotective mechanism. J Neurochem. 2008;105:1144\u201352.","journal-title":"J Neurochem"},{"key":"704_CR30","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1523\/JNEUROSCI.3178-06.2006","volume":"26","author":"AY Shih","year":"2006","unstructured":"Shih AY, Erb H, Sun X, Toda S, Kallivas PW, Murphy TH. Cystine\/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci. 2006;26:10514\u201323.","journal-title":"J Neurosci"},{"key":"704_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41537-017-0035-3","volume":"3","author":"M Fournier","year":"2017","unstructured":"Fournier M, Monin A, Ferrari C, Baumann PS, Conus P, Do K. Implication of the glutamate-cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis. NPJ Schizophr. 2017;3:31.","journal-title":"NPJ Schizophr"},{"key":"704_CR32","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/npp.2016.84","volume":"41","author":"E Plitman","year":"2016","unstructured":"Plitman E, Patel R, Chung JK, Pipitone J, Chavez S, Reyes-Madrigal F, et al. Glutamatergic metabolites, volume, and cortical thickness in antipsychotic-na\u00efve patients with first episode psychosis: implications for excitotoxicity. Neuropsychopharmacology. 2016;41:2606\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"704_CR33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archpsyc.1982.04290080001001","volume":"39","author":"JF Leckman","year":"1982","unstructured":"Leckman JF, Sholomskas D, Thompson WD, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry. 1982;39:879\u201383.","journal-title":"Arch Gen Psychiatry"},{"key":"704_CR34","unstructured":"First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 disorders, clinician version (SCID-5-CV). Arlington, VA: American Psychiatric Association; 2016."},{"key":"704_CR35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","volume":"62","author":"G Remington","year":"2017","unstructured":"Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62:604\u201316.","journal-title":"Can J Psychiatry"},{"key":"704_CR36","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"704_CR37","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/eip.12450","volume":"12","author":"R Norman","year":"2018","unstructured":"Norman R, Anderson K, MacDougall A, Manchanda R, Harricharan R, Subramanian P, et al. Stability of outcomes after 5 years of treatment in an early intervention program. Early Interv Psychiatry. 2018;12:720\u20135.","journal-title":"Early Interv Psychiatry"},{"key":"704_CR38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbn171","volume":"35","author":"PD Harvey","year":"2009","unstructured":"Harvey PD, Bellack AS. Toward a terminology of functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35:300\u20136.","journal-title":"Schizophr Bull"},{"key":"704_CR39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441\u20139.","journal-title":"Am J Psychiatry"},{"key":"704_CR40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/acps.12849","volume":"137","author":"CH Lin","year":"2018","unstructured":"Lin CH, Lin HS, Kuo CC, Wang FC, Huang YH. Early Improvement in PANSS-30, PANSS-8 and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia. Acta Psychiatr Scand. 2018;137:98\u2013108.","journal-title":"Acta Psychiatr Scand"},{"key":"704_CR41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"704_CR42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-007-0857-1","volume":"194","author":"Stefan Leucht","year":"2007","unstructured":"Leucht Stefan, Beitinger Romain, Kissling Werner. On the concept of remission in schizophrenia. Psychopharmacology. 2007;194:453\u201361.","journal-title":"Psychopharmacology"},{"key":"704_CR43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","volume":"416","author":"JM Haro","year":"2003","unstructured":"Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;416:16\u201323.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"704_CR44","doi-asserted-by":"crossref","first-page":"B16","DOI":"10.1016\/j.clinthera.2011.11.016","volume":"33","author":"C Correll","year":"2011","unstructured":"Correll C, Kishimoto T, Nielsen J, Kane J. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33:B16\u201339.","journal-title":"Clin Ther"},{"key":"704_CR45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","volume":"36","author":"M Obermeier","year":"2010","unstructured":"Obermeier M, Mayr A, Schennach-Wolff R, Seamuller F, Moller H-J, Riedel M. Should the PANSS be rescaled? Schizophr Bull. 2010;36:455\u201360.","journal-title":"Schizophr Bull"},{"key":"704_CR46","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.149.8.1119-a","volume":"149","author":"HH Goldman","year":"1992","unstructured":"Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992;149:1148\u201356.","journal-title":"Am J Psychiatry"},{"key":"704_CR47","first-page":"64","volume":"30","author":"CM Cassidy","year":"2010","unstructured":"Cassidy CM, Rabinovitch M, Schmitz N, Joober R, Malla A. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Pharmacol. 2010;30:64\u20137.","journal-title":"J Clin Pharmacol"},{"key":"704_CR48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF03166960","volume":"29","author":"I Tk\u00e1c\u0301","year":"2005","unstructured":"Tk\u00e1c\u0301 I, Gruetter R. Methodology of 1 H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson. 2005;29:139\u201357.","journal-title":"Appl Magn Reson"},{"key":"704_CR49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mrm.25094","volume":"73","author":"J Near","year":"2015","unstructured":"Near J, Edden R, Evans CJ, Paquin R, Harris A, Jezzard P. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. Magn Reson Med. 2015;73:44\u201350.","journal-title":"Magn Reson Med"},{"key":"704_CR50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/1522-2594(200010)44:4<641::AID-MRM19>3.0.CO;2-G","volume":"44","author":"R Bartha","year":"2000","unstructured":"Bartha R, Drost DJ, Menon RS, Williamson PC. Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and Eddy current correction. Magn Reson Med. 2000;44:641\u20135.","journal-title":"Magn Reson Med"},{"key":"704_CR51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1099-1492(199906)12:4<205::AID-NBM558>3.0.CO;2-1","volume":"12","author":"R Bartha","year":"1999","unstructured":"Bartha R, Drost DJ, Williamson PC. Factors affecting the quantification of short echo in vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed. 1999;12:205\u201316.","journal-title":"NMR Biomed"},{"key":"704_CR52","doi-asserted-by":"publisher","unstructured":"Wong D, Schranz A, Bartha R. Optimized in vivo brain glutamate measurement using long-echo time semi-LASER at 7 T. NMR in Biomed. 2018:e4002. https:\/\/doi.org\/10.1002\/nbm.4002.","DOI":"10.1002\/nbm.4002"},{"key":"704_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mrm.1910340105","volume":"34","author":"JA Stanley","year":"1995","unstructured":"Stanley JA, Drost DJ, Williamson PC, Thompson RT. The use of a priori knowledge to quantify short echo in vivo 1H MR spectra. Magn Reson Med. 1995;34:17\u201324.","journal-title":"Magn Reson Med"},{"key":"704_CR54","doi-asserted-by":"crossref","unstructured":"Reid MA, Salibi N, White DM, Gawne TJ, Denney TS, Lahti AC. 7T Proton Magnetic Spectroscopy of the Anterior Cingulate Cortex in First Episode Schizophrenia. Schizophr Bull. 2019;45:180\u20139.","DOI":"10.1093\/schbul\/sbx190"},{"key":"704_CR55","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/eip.12522","volume":"12","author":"HT Horsdal","year":"2018","unstructured":"Horsdal HT, Wimberley T, Kohler-Forsberg O, Baandrup L, Gasse C. Association between global functioning at first schizophrenia diagnosis and treatment resistance. Early Interv Psychiatry. 2018;12:1198\u2013202.","journal-title":"Early Interv Psychiatry"},{"key":"704_CR56","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/schbul\/sbw038","volume":"42","author":"L Xin","year":"2016","unstructured":"Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis. Schizophr Bull. 2016;42:1185\u201396.","journal-title":"Schizophr Bull"},{"key":"704_CR57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/schbul\/sbm168","volume":"34","author":"HE Hulshoff Pol","year":"2008","unstructured":"Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008;34:354\u201366.","journal-title":"Schizophr Bull"},{"key":"704_CR58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","volume":"83","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83:108\u201321.","journal-title":"Brain Res Bull"},{"key":"704_CR59","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/jcbfm.2012.33","volume":"32","author":"Y Lin","year":"2012","unstructured":"Lin Y, Stephenson MC, Xin L, Napolitano A, Morris PG. Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7T. J Cereb Blood Flow Metab. 2012;32:1484\u201395.","journal-title":"J Cereb Blood Flow Metab"},{"key":"704_CR60","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.mri.2015.06.003","volume":"33","author":"S Pradhan","year":"2015","unstructured":"Pradhan S, Bonekamp S, Gillen JS, Rowland LM, Wijtenburg SA, Edden RAE, et al. Comparison of single voxel brain MRS AT 3 T and 7 T using 32-channel head coils. Magn Reson Imaging. 2015;33:1013\u20138.","journal-title":"Magn Reson Imaging"},{"key":"704_CR61","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","volume":"27","author":"AN Samaha","year":"2007","unstructured":"Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. \u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure overtime. J Neurosci. 2007;27:2979\u201386.","journal-title":"J Neurosci"},{"key":"704_CR62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10517-015-3151-y","volume":"160","author":"SA Ivanova","year":"2015","unstructured":"Ivanova SA, Smirnova LP, Shchigoreva YG, Semke AV, Bokhan NV. Serum glutathione in patients with schizophrenia in dynamics of antipsychotic therapy. Bull Exp Biol Med. 2015;160:283\u20135.","journal-title":"Bull Exp Biol Med"},{"key":"704_CR63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pscychresns.2010.08.003","volume":"184","author":"ME Henry","year":"2010","unstructured":"Henry ME, Jensen JE, Licata SC, Ravichandran C, Butman ML, Shanahan M, et al. The acute and late CNS glutamine response to benzodiazepine challenge: a pilot pharmacokinetic study using proton magnetic resonance spectroscopy. Psychiatry Res. 2010;184:171\u20136.","journal-title":"Psychiatry Res"},{"key":"704_CR64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.drugalcdep.2013.02.028","volume":"129","author":"AP Prescot","year":"2013","unstructured":"Prescot AP, Renshaw PF, Yurgelun-Todd DA. \u03b3-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend. 2013;129:232\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"704_CR65","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbr.2013.02.028","volume":"246","author":"Y-H Sung","year":"2013","unstructured":"Sung Y-H, Carey PD, Stein DJ, Ferrett HL, Spottiswoode BS, Renshaw PF, et al. Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana. Behav Brain Res. 2013;246:154\u201361.","journal-title":"Behav Brain Res"},{"key":"704_CR66","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn RS, Rossum Inge Wintervan, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5:797\u2013807.","journal-title":"Lancet Psychiatry"},{"key":"704_CR67","doi-asserted-by":"crossref","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"M Carbon","year":"2014","unstructured":"Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16:505\u201324.","journal-title":"Dialogues Clin Neurosci"},{"key":"704_CR68","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ajp.156.10.1659","volume":"156","author":"DG Robinson","year":"1999","unstructured":"Robinson DG, Woerner MG, Alvir J, Ma J, Geisler S, Koreen A, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544\u20139.","journal-title":"Am J Psychiatry"},{"key":"704_CR69","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/schbul\/sbx093","volume":"44","author":"P Conus","year":"2018","unstructured":"Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N- acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophr Bull. 2018;44:317\u201327.","journal-title":"Schizophr Bull"},{"key":"704_CR70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acps.12862","volume":"137","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhang Q-E, Cai D-B, Yang X-H, Qiu Y, Ungvari GS, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018;137:391\u2013400.","journal-title":"Acta Psychiatr Scand"},{"key":"704_CR71","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2018.03.012","volume":"199","author":"A Breier","year":"2018","unstructured":"Breier A, Leffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, et al. Effects of 12-month double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia-spectrum disorders. Schizophr Res. 2018;199:395\u2013492.","journal-title":"Schizophr Res"},{"key":"704_CR72","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1017\/S0033291716002932","volume":"47","author":"M Rapado-Castro","year":"2017","unstructured":"Rapado-Castro M, Dod S, Bush AI, Skvarc DR, On ZX, Berk M, Dean OM, et al. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med. 2017;47:866\u201376.","journal-title":"Psychol Med"},{"key":"704_CR73","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/15622970903144004","volume":"10","author":"M Bulut","year":"2009","unstructured":"Bulut M, Savas HA, Altindag A, Virit O, Dalkilic A. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry. 2009;10:626\u20138.","journal-title":"World J Biol Psychiatry"},{"key":"704_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jnc.12398","volume":"128","author":"A Schwerk","year":"2014","unstructured":"Schwerk A, Alves FDS, Pouwels PJW, van Amelsvoort T. Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies. J Neurochem. 2014;128:1\u201387.","journal-title":"J Neurochem"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-020-0704-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-020-0704-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-020-0704-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:01:36Z","timestamp":1684602096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-0704-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1038\/s41380-020-0704-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/828608","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"25 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LP receives book royalties from Oxford University Press and income from the SPMM MRCPsych course. In the last 5 years, his or his spousal pension funds held shares of Shire Inc., and GlaxoSmithKline. LP has received investigator initiated educational grants from Otsuka, Janssen and Sunovion Canada and speaker fee from Otsuka and Janssen Canada, and Canadian Psychiatric Association. LP, MM, and KD received support from Boehringer Ingelheim to attend an investigator meeting in 2017. JT received speaker honoraria from Siemens Healthcare Canada. All other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}